Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEI + PC7A + siLIPIN1
- Development stage
- Preclinical
- Lead developer
- Qilu Hospital of Shandong University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PEI + PC7A + siLIPIN1 is a nanoparticle-based therapeutic system designed for the treatment of acute myeloid leukemia (AML). It utilizes a delivery vehicle composed of polyethylenimine (PEI) and the pH-sensitive polymer PC7A to encapsulate and deliver small interfering RNA (siRNA) targeting the LIPIN1 gene (siLIPIN1). The system is designed to counteract the effects of extrachromosomal circular DNA (eccDNA)-encoded LIPIN1, which drives DGAT1-dependent lipid droplet biogenesis and endoplasmic reticulum (ER) stress, contributing to AML progression and chemoresistance. By silencing LIPIN1, this nanoparticle system inhibits these metabolic and stress pathways, thereby suppressing tumor growth and sensitizing AML cells to chemotherapy.
- Other names
- PEI/PC7A nanoparticle systemPEI/PC7A/siLIPIN1 nanoparticle system
02
Targets
LPIN1 (Lipin 1)STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on PEI + PC7A + siLIPIN1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEI + PC7A + siLIPIN1.